Statins, aspirin and risk of venous thromboembolic events in breast cancer patients

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 1, 2014, Pages 32-38

  Shai, Ayelet ^a   Rennert, Hedy S ^a   Lavie, Ofer ^b   Ballan Haj, Muona ^c   Bitterman, Arie ^c   Steiner, Mariana ^a   Keren, Shoshana ^a   Rennert, Gad ^a  

^a CLALIT HEALTH SERVICES   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c CARMEL MEDICAL CENTER   (Israel)

Author keywords

Aspirin; Breast cancer; Cancer; Statins; Venous thromboembolic events

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TAMOXIFEN; FIBRINOLYTIC AGENT;

ADULT; AGE; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH SERVICE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; VERY ELDERLY; YOUNG ADULT; BREAST NEOPLASMS; CASE CONTROL STUDY; CLINICAL TRIAL; FACTUAL DATABASE; ISRAEL; RISK FACTOR; THROMBOEMBOLISM;

ADULT; AGE FACTORS; AGED; ASPIRIN; BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISRAEL; MIDDLE AGED; RISK FACTORS; THROMBOEMBOLISM;

EID: 84902377776     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-1015-8     Document Type: Article

References (42)

1. Chew HK, Wun T, Harvey DJ, Zhou H, White RH (2007) Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 25(1):70-76. doi:10.1200/JCO.2006.07.4393 (Pubitemid 350003053)
2. Trujillo-Santos J, Casas JM, Casado I, Samperiz AL, Quintavalla R, Sahuquillo JC, Monreal M (2011) Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Thromb Res 127(Suppl 3):S1-4. doi:10.1016/S0049-3848(11)00006-5
3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715-722. doi:10.1001/jama.293.6.715 (Pubitemid 40216041)
4. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484-3488. doi:10.1182/blood-2002-01-0108 (Pubitemid 35303914)
5. Lopez-Pedrera C, Ruiz-Limon P, Valverde-Estepa A, Barbarroja N, Rodriguez-Ariza A (2012) To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer. Curr Drug Targets 13(6):829-841
6. Schonbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109(21 Suppl 1):II18-26. doi:10.1161/01.CIR.0000129505.34151.23 (Pubitemid 38724152)
7. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G (2005) Statins and the risk of colorectal cancer. N Engl J Med 352(21):2184-2192. doi:10.1056/NEJMoa043792 (Pubitemid 40727085)
8. Beales IL, Vardi I, Dearman L (2012) Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 24(8):917-923. doi:10.1097/MEG.0b013e3283543f01
9. Ferris JS, McCoy L, Neugut AI, Wrensch M, Lai R (2012) HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer 131(6):E1031-1037. doi:10.1002/ijc.27536
10. Tsan YT, Lee CH, Wang JD, Chen PC (2012) Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 30(6):623-630. doi:10.1200/JCO.2011.36.0917
11. Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG (2012) Statin use and fatal prostate cancer: a matched case- control study. Cancer 118(16):4046-4052. doi:10.1002/cncr.26720
12. Chiu HF, Ho SC, Chang CC, Wu TN, Yang CY (2011) Statins are associated with a reduced risk of gastric cancer: a population-based case-control study. Am J Gastroenterol 106(12):2098-2103.doi:10.1038/ajg.2011.277
13. Rodriguez AL, Wojcik BM, Wrobleski SK, Myers DD Jr, Wakefield TW, Diaz JA (2012) Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis 33(4):371-382. doi:10.1007/s11239-012-0687-9
14. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A (2001) Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 161(11):1405-1410 (Pubitemid 32681161)
15. Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ (2009) HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 7(4):514-520. doi:10.1111/j.1538-7836.2008.03235.x
16. Doggen CJ, Lemaitre RN, Smith NL, Heckbert SR, Psaty BM (2004) HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2(5):700-701. doi:10.1111/j.1538-7836.2004.00696.x (Pubitemid 40185706)
17. Lacut K, Oger E, Le Gal G, Couturaud F, Louis S, Leroyer C, Mottier D (2004) Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 18(4):477-482. doi:10.1111/j.1472-8206.2004.00252.x (Pubitemid 39215361)
18. Khemasuwan D, Chae YK, Gupta S, Carpio A, Yun JH, Neagu S, Lucca AB, Valsecchi ME, Mora JI (2011) Dose-related effect of statins in venous thrombosis risk reduction. Am J Med 124(9):852-859. doi:10.1016/j.amjmed.2011.04.019
19. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S (2009) Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 67(1):99-109. doi:10.1111/j.1365-2125. 2008.03308.x
20. Hippisley-Cox J, Coupland C (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340:c2197. doi:10.1136/bmj.c2197
21. Yang CC, Jick SS, Jick H (2002) Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 53(1):101-105 (Pubitemid 34117746)
22. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360(18):1851-1861. doi:10.1056/NEJMoa0900241
23. Rahimi K, Bhala N,Kamphuisen P,Emberson J,Biere-Rafi S, Krane V,Robertson M,Wikstrand J,McMurray J (2012)Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence fromrandomised controlled trials. PLoS Med 9(9):e1001310. doi:10.1371/journal.pmed.1001310
24. Pulmonary Embolism Prevention (PEP) trial Collaborative Group (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355(9212):1295-1302
25. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71-86
26. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, openlabel, randomized trial. J Clin Oncol 29(8):986-993. doi:10.1200/ JCO.2010.31.6844
27. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4):933-939. doi:10.1182/blood-2011-03-344333 quiz 1093
28. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P (2012) Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 366(21):1959-1967. doi:10.1056/NEJMoa1114238
29. Khemasuwan D, Divietro ML, Tangdhanakanond K, Pomerantz SC, Eiger G (2010) Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 123(1):60-65. doi:10.1016/j.amjmed.2009.05.025
30. Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28(22):3577-3581. doi:10.1200/JCO.2010.28.1113
31. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245-1251 (Pubitemid 24361532)
32. Aarons CB, Cohen PA, Gower A, Reed KL, Leeman SE, Stucchi AF, Becker JM (2007) Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg 245(2):176-184. doi:10.1097/01.sla.0000236627.07927.7c (Pubitemid 46148475)
33. Patterson KA, Zhang X, Wrobleski SK, Hawley AE, Lawrence DA, Wakefield TW, Myers DD, Diaz JA (2013) Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res131(3):268-276. doi:10.1016/j.thromres.2012.12.006
34. Laumen H, Skurk T, Hauner H (2008) The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis 196(2):565-573. doi:10.1016/j. atherosclerosis.2007.06.005
35. Falanga A, Gordon SG (1985) Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 24(20):5558-5567 (Pubitemid 16228838)
36. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC (1995) Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346(8981):1004-1005
37. Rabinowich L, Steinvil A, Leshem-Rubinow E, Berliner S, Zeltser D, Rogowski O, Shalev V, Raz R, Chodick G (2012) Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation. Heart 98(24):1817-1821. doi:10.1136/heartjnl-2012-302906
38. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109(3):573-579. doi:10.1007/s10549-007-9683-8 (Pubitemid 351698864)
39. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461-1468. doi:10.1093/jnci/djr291
40. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792-1802. doi:10.1056/ NEJMoa1201735
41. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826):1591-1601. doi:10.1016/S0140-6736(12)60209-8
42. Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, Hankinson SE, Tamimi RM (2011) COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 130(2):657-662.doi:10.1007/s10549-011-1651-7